文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

银杏叶与长期新冠:用于评估纳米治疗效果的体内和体外模型

Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy.

作者信息

Akanchise Thelma, Angelova Angelina

机构信息

Université Paris-Saclay, CNRS, Institut Galien Paris-Saclay, 91400 Orsay, France.

出版信息

Pharmaceutics. 2023 May 22;15(5):1562. doi: 10.3390/pharmaceutics15051562.


DOI:10.3390/pharmaceutics15051562
PMID:37242804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10224264/
Abstract

Coronavirus infections are neuroinvasive and can provoke injury to the central nervous system (CNS) and long-term illness consequences. They may be associated with inflammatory processes due to cellular oxidative stress and an imbalanced antioxidant system. The ability of phytochemicals with antioxidant and anti-inflammatory activities, such as Ginkgo biloba, to alleviate neurological complications and brain tissue damage has attracted strong ongoing interest in the neurotherapeutic management of long COVID. Ginkgo biloba leaf extract (EGb) contains several bioactive ingredients, e.g., bilobalide, quercetin, ginkgolides A-C, kaempferol, isorhamnetin, and luteolin. They have various pharmacological and medicinal effects, including memory and cognitive improvement. Ginkgo biloba, through its anti-apoptotic, antioxidant, and anti-inflammatory activities, impacts cognitive function and other illness conditions like those in long COVID. While preclinical research on the antioxidant therapies for neuroprotection has shown promising results, clinical translation remains slow due to several challenges (e.g., low drug bioavailability, limited half-life, instability, restricted delivery to target tissues, and poor antioxidant capacity). This review emphasizes the advantages of nanotherapies using nanoparticle drug delivery approaches to overcome these challenges. Various experimental techniques shed light on the molecular mechanisms underlying the oxidative stress response in the nervous system and help comprehend the pathophysiology of the neurological sequelae of SARS-CoV-2 infection. To develop novel therapeutic agents and drug delivery systems, several methods for mimicking oxidative stress conditions have been used (e.g., lipid peroxidation products, mitochondrial respiratory chain inhibitors, and models of ischemic brain damage). We hypothesize the beneficial effects of EGb in the neurotherapeutic management of long-term COVID-19 symptoms, evaluated using either in vitro cellular or in vivo animal models of oxidative stress.

摘要

冠状病毒感染具有神经侵袭性,可引发中枢神经系统(CNS)损伤及长期疾病后果。它们可能与细胞氧化应激和抗氧化系统失衡导致的炎症过程有关。具有抗氧化和抗炎活性的植物化学物质,如银杏,减轻神经并发症和脑组织损伤的能力,在长期新冠的神经治疗管理中引起了持续的浓厚兴趣。银杏叶提取物(EGb)含有多种生物活性成分,如白果内酯、槲皮素、银杏内酯A - C、山奈酚、异鼠李素和木犀草素。它们具有多种药理和药用作用,包括改善记忆和认知。银杏通过其抗凋亡、抗氧化和抗炎活性,影响认知功能以及长期新冠等其他疾病状况。虽然神经保护抗氧化疗法的临床前研究已显示出有前景的结果,但由于若干挑战(如药物生物利用度低、半衰期有限、稳定性差、靶向组织递送受限以及抗氧化能力不足),临床转化仍然缓慢。本综述强调了使用纳米颗粒药物递送方法的纳米疗法在克服这些挑战方面的优势。各种实验技术揭示了神经系统氧化应激反应的分子机制,并有助于理解SARS-CoV-2感染神经后遗症的病理生理学。为开发新型治疗剂和药物递送系统,已使用了几种模拟氧化应激条件的方法(如脂质过氧化产物、线粒体呼吸链抑制剂和缺血性脑损伤模型)。我们假设EGb在长期新冠症状的神经治疗管理中具有有益作用,这可通过氧化应激的体外细胞模型或体内动物模型进行评估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/dd21020ca0c6/pharmaceutics-15-01562-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/dfa6b15c1208/pharmaceutics-15-01562-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/3d08345f838c/pharmaceutics-15-01562-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/85d094d22ef6/pharmaceutics-15-01562-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/d4f4230976d8/pharmaceutics-15-01562-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/fd86b78bc311/pharmaceutics-15-01562-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/1270854b0dcc/pharmaceutics-15-01562-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/c2bf1e8eec62/pharmaceutics-15-01562-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/0f2d9b5b35c7/pharmaceutics-15-01562-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/7b94dd9fe6bc/pharmaceutics-15-01562-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/dd21020ca0c6/pharmaceutics-15-01562-g010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/dfa6b15c1208/pharmaceutics-15-01562-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/3d08345f838c/pharmaceutics-15-01562-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/85d094d22ef6/pharmaceutics-15-01562-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/d4f4230976d8/pharmaceutics-15-01562-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/fd86b78bc311/pharmaceutics-15-01562-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/1270854b0dcc/pharmaceutics-15-01562-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/c2bf1e8eec62/pharmaceutics-15-01562-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/0f2d9b5b35c7/pharmaceutics-15-01562-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/7b94dd9fe6bc/pharmaceutics-15-01562-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a5b/10224264/dd21020ca0c6/pharmaceutics-15-01562-g010.jpg

相似文献

[1]
Ginkgo Biloba and Long COVID: In Vivo and In Vitro Models for the Evaluation of Nanotherapeutic Efficacy.

Pharmaceutics. 2023-5-22

[2]
EGb 761: ginkgo biloba extract, Ginkor.

Drugs R D. 2003

[3]
[Ginkgo biloba extract (EGb 761). State of knowledge in the dawn of the year 2000].

Ann Pharm Fr. 1999-7

[4]
Identification of kaempferol as a monoamine oxidase inhibitor and potential Neuroprotectant in extracts of Ginkgo biloba leaves.

J Pharm Pharmacol. 2000-4

[5]
Pharmacokinetic herb-disease-drug interactions: Effect of ginkgo biloba extract on the pharmacokinetics of pitavastatin, a substrate of Oatp1b2, in rats with non-alcoholic fatty liver disease.

J Ethnopharmacol. 2021-11-15

[6]
Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease.

Pharmacopsychiatry. 2003-6

[7]
A network pharmacology-based strategy for predicting the protective mechanism of Ginkgo biloba on damaged retinal ganglion cells.

Chin J Nat Med. 2022-1

[8]
Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.

Antioxidants (Basel). 2023-2-6

[9]
Ginkgo biloba in the management of the COVID-19 severity.

Arch Pharm (Weinheim). 2022-10

[10]
Effects of Ginkgo biloba on Diseases Related to Oxidative Stress.

Planta Med. 2020-2-25

引用本文的文献

[1]
Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery.

Int J Mol Sci. 2025-7-30

[2]
A Review on Novel Techniques Used for Drying Medicinal Plants and Its Applications.

Int J Biomater. 2025-7-9

[3]
Unveiling the therapeutic potential of natural products in Alzheimer's disease: insights from , , and clinical studies.

Front Pharmacol. 2025-6-23

[4]
Understanding chronic inflammation: couplings between cytokines, ROS, NO, Ca , HIF-1α, Nrf2 and autophagy.

Front Immunol. 2025-4-8

[5]
Exploring Bioactive Phytomedicines for Advancing Pulmonary Infection Management: Insights and Future Prospects.

Phytother Res. 2024-12

[6]
Nano-Ayurvedic Medicine Approaches Using -Phytochemicals Functionalized Gold Nanoparticles Against Breast Cancer.

Nanotechnol Sci Appl. 2024-9-23

[7]
Ginkgo biloba extract inhibits hippocampal neuronal injury caused by mitochondrial oxidative stress in a rat model of Alzheimer's disease.

PLoS One. 2024

[8]
Roles of Integrin in Cardiovascular Diseases: From Basic Research to Clinical Implications.

Int J Mol Sci. 2024-4-7

[9]
Possible Role of Cannabis in the Management of Neuroinflammation in Patients with Post-COVID Condition.

Int J Mol Sci. 2024-3-29

[10]
Neurovascular coupling impairment as a mechanism for cognitive deficits in COVID-19.

Brain Commun. 2024-3-7

本文引用的文献

[1]
Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.

Antioxidants (Basel). 2023-2-6

[2]
Identifying the Anti-MERS-CoV and Anti-HcoV-229E Potential Drugs from the Leaves Extract and Its Eco-Friendly Synthesis of Silver Nanoparticles.

Molecules. 2023-2-1

[3]
Erratum to "Long COVID: An overview" [Diabetes Metabol. Syndr. Clin. Res. Rev. (2021) 869-875].

Diabetes Metab Syndr. 2022-12

[4]
Efficient Sustained-Release Nanoparticle Delivery System Protects Nigral Neurons in a Toxin Model of Parkinson's Disease.

Pharmaceutics. 2022-8-18

[5]
Cocoa Extract Provides Protection against 6-OHDA Toxicity in SH-SY5Y Dopaminergic Neurons by Targeting PERK.

Biomedicines. 2022-8-18

[6]
Comparative study between effects of ginkgo biloba extract and extract loaded on gold nanoparticles on hepatotoxicity induced by potassium bromate.

Environ Sci Pollut Res Int. 2023-1

[7]
Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches.

J Clin Invest. 2022-8-1

[8]
Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls.

Antioxidants (Basel). 2022-6-3

[9]
Ginkgo biloba in the management of the COVID-19 severity.

Arch Pharm (Weinheim). 2022-10

[10]
Novel Luteolin-Loaded Chitosan Decorated Nanoparticles for Brain-Targeting Delivery in a Sporadic Alzheimer's Disease Mouse Model: Focus on Antioxidant, Anti-Inflammatory, and Amyloidogenic Pathways.

Pharmaceutics. 2022-5-6

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索